Home › Laryngeal Cancer › Massachusetts
Laryngeal Cancer clinical trials in Massachusetts
7 studies for Laryngeal Cancer are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- Boston Medical Center, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06589804BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Baystate Medical Center, Springfield
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05136196Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- Tufts Medical Center, Boston
- Tufts Medical Center Cancer Center Stoneham, Stoneham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT02734537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Boston Medical Center, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06532279Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699CONFIRM: Magnetic Resonance Guided Radiation Therapy
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Feb 9, 2026 · NCT04368702SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.